Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD makes Threshold licence payment after target achieved

MSD makes Threshold licence payment after target achieved

2nd January 2014

Merck, Sharpe and Dohme (MSD) is to make a milestone payment of $12.5 million (7.54 million pounds) to Threshold Pharmaceuticals following the enrollment of 620 patients in its phase III trial of investigational hypnoxia-targeted drug TH-302.

This number of patients with advanced soft tissue sarcoma was a pre-defined target as part of the global license and co-development agreement between the two companies.

Threshold has joined forces with the Sarcoma Alliance for Research through Collaboration to conduct the international, randomised phase III trial of TH-302. 

Barry Selick, the firm's chief executive officer, said: "We hope that TH-302 will ultimately be shown to be both safe and efficacious in this patient population for which there is an urgent unmet medical need."

Sarcomas are aggressive forms of cancer of connective body tissues and the current treatment options are limited, with soft tissue sarcomas usually treated with a combination of surgery, chemotherapy and radiation.

It is estimated that around 36,000 new soft tissue sarcomas were diagnosed across the US and Europe in 2013.ADNFCR-8000103-ID-801677876-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.